Q2 Earnings Forecast for 908 Devices Issued By William Blair

908 Devices Inc. (NASDAQ:MASS - Free Report) - Equities research analysts at William Blair increased their Q2 2025 EPS estimates for shares of 908 Devices in a research note issued on Wednesday, May 14th. William Blair analyst M. Larew now forecasts that the company will post earnings per share of ($0.13) for the quarter, up from their prior forecast of ($0.18). The consensus estimate for 908 Devices' current full-year earnings is ($1.99) per share. William Blair also issued estimates for 908 Devices' Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.28) EPS.

908 Devices (NASDAQ:MASS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.05. 908 Devices had a negative net margin of 109.11% and a negative return on equity of 24.60%. The business had revenue of $11.78 million for the quarter, compared to analysts' expectations of $11.90 million.

Separately, Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a research note on Saturday, May 10th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $5.33.

908 Devices Trading Up 1.3%

908 Devices stock opened at $4.58 on Monday. The stock has a market cap of $163.69 million, a price-to-earnings ratio of -2.59 and a beta of 0.26. The company's 50-day moving average price is $4.60 and its two-hundred day moving average price is $3.27. 908 Devices has a 52 week low of $1.81 and a 52 week high of $7.03.

Institutional Trading of 908 Devices

A number of institutional investors have recently added to or reduced their stakes in MASS. AWM Investment Company Inc. lifted its stake in 908 Devices by 210.6% in the first quarter. AWM Investment Company Inc. now owns 5,199,924 shares of the company's stock valued at $23,296,000 after acquiring an additional 3,526,000 shares during the last quarter. First Light Asset Management LLC acquired a new position in 908 Devices during the 1st quarter valued at $7,621,000. Invesco Ltd. acquired a new position in 908 Devices during the 1st quarter valued at $2,910,000. Essex Investment Management Co. LLC bought a new stake in 908 Devices in the 1st quarter valued at $2,153,000. Finally, Prescott Group Capital Management L.L.C. bought a new stake in 908 Devices in the 4th quarter valued at $330,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at 908 Devices

In other 908 Devices news, Director Mark Spoto bought 10,000 shares of 908 Devices stock in a transaction on Wednesday, May 14th. The stock was purchased at an average cost of $4.29 per share, for a total transaction of $42,900.00. Following the completion of the purchase, the director now directly owns 62,971 shares of the company's stock, valued at $270,145.59. The trade was a 18.88% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 27.70% of the stock is currently owned by insiders.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.